NasdaqCM - Nasdaq Real Time Price USD

Sonoma Pharmaceuticals, Inc. (SNOA)

0.1590 -0.0019 (-1.18%)
At close: April 26 at 4:00 PM EDT
0.1566 -0.00 (-1.51%)
After hours: April 26 at 6:07 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Ms. Amy M. Trombly CEO, President & Director 524.19k -- 1968
Mr. Jerome J. Dvonch Chief Financial Officer 281.16k -- 1968
Mr. Bruce Thornton COO & Corporate Secretary 448.87k -- 1964
Mr. John Dal Poggetto Controller 433.36k -- 1972

Sonoma Pharmaceuticals, Inc.

5445 Conestoga Court
Suite 150
Boulder, CO 80301
United States
800 759 9305 https://www.sonomapharma.com
Sector: 
Healthcare
Full Time Employees: 
9

Description

Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis. It also provides Gramaderm for the treatment of topical mild to moderate acne; Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens; Ocucyn eyelid and eyelash cleanser; Microdacyn60 oral care solution for the treatment of mouth and throat infections; and Podiacyn, a foot care product. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; MicrocynVS, a veterinarian-strength animal care product used in vet clinics and animal hospitals; Nanocyn, a hospital-grade disinfectant; Acuicyn, an antimicrobial prescription solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; and Sinudox for nasal irrigation. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.

Corporate Governance

Sonoma Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

Jun 19, 2024 - Jun 24, 2024
Sonoma Pharmaceuticals, Inc. Earnings Call

Related Tickers

LSDI Lucy Scientific Discovery Inc.
0.7597
-12.58%
 
SHPH Shuttle Pharmaceuticals Holdings, Inc.
0.3850
-0.90%
 
BFRI Biofrontera Inc.
1.5900
-7.02%
 
SXTC China SXT Pharmaceuticals, Inc.
1.0500
+1.94%
 
PTPI Petros Pharmaceuticals, Inc.
0.6399
0.00%
 
AKAN Akanda Corp.
0.1030
+12.57%
 
YCBD cbdMD, Inc.
0.8711
-3.21%
 
OPTN OptiNose, Inc.
0.8604
-4.93%
 
CPHI China Pharma Holdings, Inc.
0.3023
-7.27%
 
CNADF CanadaBis Capital Inc.
0.0650
0.00%